The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Oxford Biomedica plc (OXB) provides process development and manufacturing services tailored to pharmaceutical and biotech companies in the cell and gene therapy sector. The company specialises in viral vector manufacturing, including lentiviral, AAV, and adenoviral vectors. Notable brands associated with OXB include the Lentivector platform, inAAVate, and AdenoVate. OXB's products and services are utilised by clients in the pharmaceutical and biotechnology industries to develop and scale cell and gene therapy products across various therapeutic areas. Based on this platform, It has a partnership and license agreement with other companies to develop potential gene and cell therapy products. OXB operates globally, targeting markets in the cell and gene therapy sector. The company has a presence in different locations in the UK and in Boston, the US. Oxford Biomedica is headquartered in Oxford, England, United Kingdom.Oxford BioMedica Plc Key Recent Developments
- Oct 30, 2025: VVMF Announces Strategic Collaboration With OXB, With View to Licencing AAV and Lentiviral Vector Platforms as First Priority
- Oct 27, 2025: OXB to Participate in Upcoming Investor Conferences and Events
- Oct 20, 2025: Oxford BioMedica - Board Change
- Oct 13, 2025: OXB Acquires FDA-Approved Former Resilience Site in Research Triangle
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agenus Inc
- Silence Therapeutics Plc
- Genetix Biotherapeutics Inc
- Almac Group Ltd
- Transgene SA
- VectorBuilder Inc

